TrialESMO open2022

A multicentre, randomised, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (DESIREE).

M Schmidt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.